Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis

Cheung, Michelle C M; Walker, Alex J; Hudson, Benjamin E; Verma, Suman; McLauchlan, John; Mutimer, David J; Brown, Ashley; Gelson, William T H; MacDonald, Douglas C; Agarwal, Kosh; Foster, Graham R; Irving, William L; HCV Research UK

DOI:
10.1016/j.jhep.2016.06.019

Outcomes a year after successful direct acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis

Michelle CM Cheung

Alex J Walker

Benjamin E Hudson

Suman Verma

John McLauchlan

David J Mutimer

Ashley Brown

William TH Gelson

Douglas C MacDonald

Kosh Agarwal

Graham R Foster

William L Irving

HCV Research UK

Contents

HCV Research UK Investigators

Abouda G (Hull Royal Infirmary), Agarwal K (Kings College Hospital, London), Ala A (Frimley Park Hospital), Aldersley M (St James's University Hospital, Leeds), Alexander G (Addenbrookes Hospital, Cambridge), Aspinall R (Queen Alexandra Hospital, Portsmouth), Barclay S (Glasgow Royal Infirmary), Barnes E (John Radcliffe Hospital, Oxford), Brown A (St Mary's Hospital, London), Benselin J (University of Nottingham), Butterworth J (Royal Shrewsbury Hospital), Ch'ng C (Singleton Hospital, Swansea), Chadwick D (James Cook University Hospital, Middlesbrough), Corless L (Hull Royal Infirmary), Cramp M (Derriford Hospital, Plymouth), Datta S (Southern General Hospital & Glasgow Victoria Hospital), Dillon J (Ninewells Hospital, Dundee), Elsharkawy A (Queen Elizabeth Hospital, Birmingham), Forton D (St George's Hospital, London), Foster G (The London Hospital), Foxton M (Chelsea & Westminster Hospital), Fraser A (Aberdeen Royal Infirmary), Gelson W (Addenbrookes Hospital, Cambridge), Goldberg D (Health Protection Scotland), Gorard D (Wycombe Hospital), Gordon F (Bristol Royal Infirmary), Gore C (Hepatitis C Trust), Hayes P (Royal Infirmary of Edinburgh), Heydtmann M (Royal Alexandra Hospital, Glasgow), Higham A (Royal Lancaster Infirmary), Holtham E (University of Nottingham), Hubscher S (University of Birmingham), Hutchinson S (Glasgow Caledonian University), Irving W (University of Nottingham), Jenkins N (Birmingham Heartlands Hospital), Kelly D (Birmingham Children's Hospital), Knowles J (James Cook University Hospital, Middlesbrough), Langford A (British Liver Trust), Lawson A, (Royal Derby Hospital), Leen C (Western General Hospital, Edinburgh), McDonald S (University of Glasgow), McLauchlan J (University of Glasgow), McPherson S (Freeman Hospital, Newcastle), Mills P

(Gartnavel General Hospital, Glasgow), Moreea S (Bradford Teaching Hospitals Foundation Trust), Mutimer D (Queen Elizabeth Hospital, Birmingham), Neal K (Public Health England), Patel A (University of Glasgow), Prince M (Manchester Royal Infirmary), Quinlan P (University of Nottingham), Ramsay M (Public Health England), Reddy Y (Royal Blackburn Hospital), Richardson P (Royal Liverpool University Hospital), Rosenberg W (Royal Free Hospital & University College Hospital), Ryder S (Queen's Medical Centre, Nottingham), Shields P (Royal Preston Hospital), Shorrock C (Blackpool Victoria Hospital), Simmonds P (University of Edinburgh), Singhal S (Sandwell & City Hospitals, Birmingham), Sreedharan A (Lincoln County Hospital), Srirajaskanthan R (University Hospital Lewisham), Stone B (Royal Hallamshire Hospital, Sheffield), Thursz M (St Mary's Hospital, London), Tibble J (Brighton and Sussex University Hospitals NHS Trust), Ustianowski, A (North Manchester General Hospital), Verma S (Brighton and Sussex University Hospitals NHS Trust), Wilkes B (University of Nottingham), Wiselka M (Leicester Royal Infirmary), Wright M (Southampton General Hospital)



Supplementary Fig. 1. MELD score changes between baseline to month 6 and month 15. Top panel shows MELD change at month 6 (282 comparative scores available) and bottom panel shows MELD change at month 15 (74 comparative scores available – MELD at month 15 was calculated if laboratory results were available within a two month window of month 15). Patients transplanted at month 6 and 15 respectively were excluded.

Supplementary table 1. Virological outcome (intention to treat) by treatment regime and genotype

All		N	SVR24 (%)	Virological failure (%)	Died before SVR 24(%)	Not available / lost to follow up (%)
G1	Sof/LDV	13	76.9	7.7	15.4	0.0
	Sof/LDV/RBV	148	89.2	5.4	3.4	2.0
	Sof/DCV	3	66.7	33.3	0.0	0.0
	Sof/DCV/RBV	34	88.2	2.9	2.9	5.9
G3	Sof/LDV	5	40.0	60.0	0.0	0.0
	Sof/LDV/RBV	57	61.4	33.3	5.3	0.0
	Sof/DCV	5	40.0	0.0	60.0	0.0
	Sof/DCV/RBV	104	69.2	16.3	10.6	3.8
Other genotypes	Sof/LDV	0	0.0	0.0	0.0	0.0
	Sof/LDV/RBV	23	87.0	13.0	0.0	0.0
	Sof/DCV	3	100.0	0.0	0.0	0.0
	Sof/DCV/RBV	11	81.8	0.0	9.1	9.1

Supplementary table 2. Serious adverse events in treated patients. Events after month 6 were reported only for patients who achieved SVR24, since non-SVR24 patients received retreatment. Note each patient may be counted more than once if multiple events occurred.

	SVR24 (n=317)			Non-SVR24 (n=89)		
	Month 0-6	Month 6-15	Month 0-15	Month 0-6		
Decompensation	46 (14.5%)	16 (5.0%)	52(16.4%)	26 (29.2%)	-	-
Sepsis	21 (6.6%)	9 (2.8%)	26 (8.2%)	6 (6.7%)	-	-
All cause hospitalisations	94 (29.7%)	62 (19.6%)	116 (36.6%)	39 (43.8%)	-	-

Supplementary table 3. Outcomes within 6 months in patients after excluding active alcohol users at baseline. ** difference between treated and untreated p=0.025

	N	Deaths	Hepatocellular carcinoma	Liver transplants	Decompensation
Treated	353	12 (3.4%)	15 (4.2%)	27 (7.6%)	66 (18.7%) *
Untreated	201	9 (4.5%)	9 (4.5%)	10 (5.0%)	54 (26.9%) *
Untreated – subsequently received DAA	106	0 (0.0%)	4 (3.8%)	3 (2.8%)	26 (24.5%)

Supplementary table 4. MELD score change at month 6 and 15 according to baseline MELD, for patients with SVR24 who did not receive a transplant during this period.

Baseline MELD	N	Average MELD – baseline	Average MELD change – month 6 (range)	Average MELD – month 6	Average MELD change – month 15	Average MELD – month 15
</= 9	87	8.3	+1.8 (-2 to 5)	8.0	+0.74 (-2 to 4)	8.5
10-14	166	11.8	- 0.77 (-6 to 7)	10.9	+0.71 (-6 to 10)	12.2
>15	45	17	-2.7 (-12 to 4)	14.7	- 1.4 (-7 to 10)	15.0

Supplementary table 5. MELD score change at month 15 according to baseline MELD, for patients with SVR24 who did not receive a transplant during this period.

	Month 15 (n, %)		
Baseline	</=9	10-14	>15
</=9 (n=26)	19 (73.1%)	7 (26.9%)	0 (0%)
10-14 (n=41)	10 (24.4%)	20 (48.8%)	11 (26.8%)
>15 (n=7)	1 (14.3%)	3 (42.9%)	3 (42.9%)